Sponsors

Screening for CPE: aiming to limit the rise of antimicrobial resistance

The increasing incidence of carbapenemase-producing Enterobacterales is an imminent public health concern. Here, Terry Whalley highlights the importance of raising awareness of this among decision-makers in a healthcare environment, and discusses how practical and implementable screening could help trusts stay one step ahead of this global threat.

Antimicrobial resistance (AMR) presents a major challenge to healthcare across the world, threatening our ability to treat common infections and leading to prolonged hospital stays, mounting treatment costs and higher mortality rates. 

The latest in a long line of drug-resistant pathogens are carbapenemase-producing Enterobacterales (CPE), and their increasing incidence presents an imminent public health concern that could drastically affect NHS trusts throughout the UK. Screening high-risk patients for CPE is an effective way to identify and isolate cases at an individual level, so that measures can be implemented to curb contamination and effectively prevent widespread outbreaks. 

This article highlights the importance of raising awareness of CPE among decision-makers and board members in a healthcare environment, and discusses how practical and implementable screening could help trusts stay one step ahead of this global threat.

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024

Pathology Visions 24

Hyatt Regency, Orlando, FL
3-5 November, 2025

Medica

Messe Dusseldorf
11-14 November, 2024

POCT-for-Scot: Bringing the future to you

SEC Arena, Glasgow
14 November, 2024